Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Overdosing on chemo: A common gene test could save hundreds of lives each year

One January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died in excruciating pain from the very drug meant to prolong her life.

26 Mar 2024

Study: Most stroke survivors can safely take two types of common antidepressants

Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2024.

1 Feb 2024

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for both types of events.

29 Aug 2023

Common genetic variants reduce clopidogrel effectiveness in British South Asians

Clopidogrel is a commonly prescribed medication used to prevent further heart attacks after an initial event. It needs to be activated in the body to be effective.

21 Aug 2023

Medications for chronic diseases can impair thermoregulation, especially in hot weather

Medications to treat various chronic diseases may hinder the body’s ability to lose heat and regulate its core temperature to optimal levels.

17 Aug 2023

Researchers discover a new switching point that regulates hemostasis and thrombosis

The glycoprotein V of the blood platelets is an important switch point for hemostasis and thrombus formation. This new finding could have great clinical potential.

24 Mar 2023

Dual antiplatelet therapy for minor or a warning stroke is underused especially among women

Despite evidence that starting two blood-thinning medications shortly after a minor stroke or a warning stroke (transient ischemic attack - TIA) may prevent a second – possibly more serious – clot-caused stroke within a few months, the treatment regimen is underused especially among women, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2023.

2 Feb 2023

What are the long-term outcomes of critical COVID-19 patients?

Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.

21 Dec 2022

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Investigating plasma signatures of platelet-derived proteins in acute pulmonary embolism

In a new study, researchers determined plasma signatures of proteins related to or derived from platelets in acute isolated pulmonary embolism (iPE) and deep vein thrombosis-associated PE (DVT-PE), compared to isolated DVT (iDVT).

17 Oct 2022

What is currently known about the mechanism and treatments of long COVID?

The current understanding of the mechanisms underlying long COVID or post-acute sequelae of COVID and potential treatment methods that show promise in long COVID management.

6 Sep 2022

Clopidogrel monotherapy linked with reduced risk of net adverse clinical events, study finds

Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during the chronic maintenance period.

20 May 2022

Scientists identify innovative treatment approach for arterial thromboses

Scientists have shown in an animal model that the CXCL12 messenger could be suitable as a target structure for the treatment of blood-clotting disorders.

21 Apr 2022

Patients treated with edoxaban after TAVR do not find reduction in mini strokes, blood clots in the brain

Patients treated with the blood thinner edoxaban for six months after a heart valve replacement procedure experienced fewer symptomless blood clots inside the heart valve replacement than patients who were treated with two antiplatelet drugs, according to data presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

AAN issues practice advisory for preventing second stroke in people with intracranial atherosclerosis

The use of medications and exercise is more beneficial in preventing a second stroke in people with intracranial atherosclerosis than placing a stent in the blood vessel, according to a new practice advisory issued by the American Academy of Neurology.

22 Mar 2022

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.

3 Mar 2022

Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients

A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds.

15 Nov 2021

Trial examines differences in gastrointestinal effects of antiplatelet therapy after PCI

Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy.

8 Nov 2021

Research reveals a new role for platelets in COVID-19 blood vessel damage

Abnormal crosstalk between blood platelets and cells lining blood vessels is one cause of deadly organ damage in patients with severe COVID-19, a new study finds.

8 Sep 2021